A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer

Background: Capecitabine plus oxaliplatin (XELOX) is considered one of the primary chemotherapy regimens for patients with metastatic colorectal cancer (CRC). Oxaliplatin plus S-1 (OS) has also demonstrated significant efficacy in CRC. We performed this randomized phase II study to evaluate the effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jung Han, Zang, Dae Young, Chung, Ik-Joo, Cho, Sang-Hee, Park, Keon Uk, Oh, Ho-Suck, Lee, Kyung Hee, Lee, Bong Hwa, Kim, Min-Jeong, Park, Choong Kee, Han, Boram, Kim, Hyeong Su, Choi, Dae Ro, Song, Hun Ho, Jung, Joo Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565854/
https://www.ncbi.nlm.nih.gov/pubmed/26366218
http://dx.doi.org/10.7150/jca.12819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565854/
https://www.ncbi.nlm.nih.gov/pubmed/26366218
http://dx.doi.org/10.7150/jca.12819

Ejemplares similares